Cite
Karachaliou GS, Alkallas R, Carroll SB, et al. The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma. BMC Cancer. 2022;22(1):38doi: 10.1186/s12885-021-08908-z.
Karachaliou, G. S., Alkallas, R., Carroll, S. B., Caressi, C., Zakria, D., Patel, N. M., Trembath, D. G., Ezzell, J. A., Pegna, G. J., Googe, P. B., Galeotti, J. P., Ayvali, F., Collichio, F. A., Lee, C. B., Ollila, D. W., Gulley, M. L., Johnson, D. B., Kim, K. B., Watson, I. R., & Moschos, S. J. (2022). The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma. BMC cancer, 22(1), 38. https://doi.org/10.1186/s12885-021-08908-z
Karachaliou, Georgia Sofia, et al. "The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma." BMC cancer vol. 22,1 (2022): 38. doi: https://doi.org/10.1186/s12885-021-08908-z
Karachaliou GS, Alkallas R, Carroll SB, Caressi C, Zakria D, Patel NM, Trembath DG, Ezzell JA, Pegna GJ, Googe PB, Galeotti JP, Ayvali F, Collichio FA, Lee CB, Ollila DW, Gulley ML, Johnson DB, Kim KB, Watson IR, Moschos SJ. The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma. BMC Cancer. 2022 Jan 05;22(1):38. doi: 10.1186/s12885-021-08908-z. PMID: 34986841.
Copy
Download .nbib